

## ADULT I.V. PUSH MEDICATIONS

### LEVEL OF CARE:

|                     |      |  |
|---------------------|------|--|
| CDU                 | CDU  | Unit with patient on continuous telemetry monitoring (UCMC & HMH)  |
| Critical care units | CC   | Nursing units equipped to provide continuous ventilator and cardiac support and intervention, these include ICUs, OR, ED, PACU, CV Lab, CCE                      |
| IMC                 | IMC  | Nursing units equipped to provide continuous cardiac monitoring and support.   |
| Cardiac/Telemetry   | C-T  | Nursing units equipped to provide continuous cardiac monitoring and support-designated as Cardiac Unit with Telemetry: CDU (1W), 3E, 3ET, 3S, Med/surg Flex Unit |
| Med-Surg/Telemetry  | MS-T | Nursing units with patient on continuous Telemetry Monitoring: 3W, 2W, 4T, 3T  |
| CVPR                | CVPR |  |
| Med-Surg            | MS   | General Nursing Units  |
| Family Birth Place  | FBP  | FBP  |
|                     |      |  |

| GENERIC NAME (BRAND NAME) | UNIT SPECIFICATION   | DRUG CLASS                  | IVP RATE                                  | MAXIMUM SINGLE DOSE  | DILUTIONS   | MONITORING CONSIDERATIONS  | ADVERSE REACTIONS/COMMENTS             |
|---------------------------|--|-----------------------------|---|--|---|--|--|
| Acetazolamide (Diamox)    | CC, IMC  | Diuretic                    | 250-500 mg/min                            | 1g   | Dilute to 100 mg/mL solution with sterile water   | BP, BMP, CO2 urine output  | Hypotension; dilute with sterile water |
| Adenosine (Adenocard)     | Any unit during Code Blue A or rapid response<br>CC, IMC, C-T                                | Antiarrhythmic, vasodilator | SVT- Over 1-2 seconds, flush line with NS | 12 mg  | Do not dilute<br><br>Flush each dose with 20 mL for adults.                                       | <b>Heart monitor must be in room when administering</b> , monitor ECG, HR, BP  | Chest pain, flushing common            |
| Alteplase (Activase)      | CC<br><br>Exception: (Doses for catheter occlusion may be administered at any level of care) | Thrombolytic Agent          | 2 mins                                    | For Catheter occlusion--2 mg<br><br>For Code Blue--100 mg<br><br>For Acute Ischemic Stroke--9 mg | Dilute in equal volume of 0.9% sodium chloride or D5W to yield a final concentration of 0.5 mg/mL | For catheter occlusion:<br>Assess catheter function after 30 min dwell time by attempting aspirate blood. If not functional, let dwell for total 120 min. If not functional, repeat dose x 1<br><br>For all patients: Signs of external bleeding at venipuncture sites<br>signs of internal bleeding (hypotension, hematuria, hematemesis, melena), CBC, aPTT, angioedema is rare<br><br>For ischemic stroke: Neurological assessment and check BP q 15min during infusion and q 30min for next 6 hrs, then q1h until 24 h post treatment; ↑ frequency if patient hypertensive (SBP >180 mmHg or DBP >105 mmHg) If patient experience severe headache, | Hypotension, Fever                     |

| GENERIC NAME<br>(BRAND NAME) | UNIT SPECIFICATION   | DRUG CLASS               | IVP RATE   | MAXIMUM SINGLE DOSE  | DILUTIONS  | MONITORING CONSIDERATIONS   | ADVERSE REACTIONS/COMMENTS   |
|------------------------------|--|--------------------------|--|--|--|---|--|
|                              |  |                          |  |  |  | nausea or vomiting, notify HO and BAT team immediately.   |  |
| Amiodarone<br>(Cordarone)    | ANY UNIT DURING CODE BLUE A  | Antiarrhythmic           | Initial: 300 mg rapid bolus; if pulseless VT or VF continues after subsequent defibrillation attempt or recurs, administer supplemental dose of 150 mg | 300 mg   | May be diluted in 20-30 cc D5W   | HR, BP, ECG (QTc)<br>***Loading dose is given in a setting with continuous cardiac monitoring***  | Hypotension, arrhythmias, contraindicated in pregnancy   |
| Atropine                     | Any unit during Code Blue A or rapid response, CC, C-T, IMC                        | Anticholinergic          | Rapid IVP  | 1 mg   | Do not dilute  | Continuous cardiac monitoring, HR, BP, mental status. May be ineffective in heart transplant patients.  | Do not give less than 0.5 mg   |
| Benztropine<br>(Cogentin)    | ALL  | Anticholinergic          | Over 1 min   | 2mg  | Do not dilute  | HR  | Anti-cholinergic side effects  |
| Bumetanide<br>(Bumex)        | ALL  | Diuretic                 | 1-2 min  | 1 mg   | Do not dilute  | BP, BMP, CO2, urine output  | Ototoxicity, ↓BP, ↓ electrolytes, ↑ glucose, metabolic alkalosis   |
| Calcium chloride             | ANY UNITS DURING CODE BLUE A<br><b>Any units for hyperkalemia with EKG changes</b> | Electrolyte              | Over 2-5 min   | 1000 mg  | Do not dilute-ADMINISTER THROUGH LOWEST Y-SITE OF RAPIDLY RUNNING FLUID                                    | Continuous cardiac monitoring during rapid infusion, serum Ca, and/or ionized Ca may be rechecked after repletion,;   | Cardiac arrest/hyperkalemia, EMERGENCY ONLY, if non-emergent condition, use Calcium Gluconate as an infusion. May cause hypophosphatemia.<br><b>-CENTRAL LINE ONLY for hyperkalemia with EKG changes</b> |
| Calcium Gluconate            | All units during Code Blue A<br><b>Any units for hyperkalemia with EKG changes</b> | Electrolyte              | Over 5-10 min  | 1000 mg  | Do not dilute  | continuous cardiac monitoring during rapid infusion, serum Ca, and/or ionized Ca may be rechecked after repletion   | Arrhythmia, bradycardia, cardiac arrest, hypotension, vasodilation, and syncope may occur following rapid I.V. injection   |
| Cisatrocorium<br>(Nimbex)    | CC   | Paralytic                | Over 1-2 min   | 0.2 mg/kg<br>Use Ideal Body Weight (IBW) in obese patients | Do not dilute  | Train of 4 via peripheral nerve stimulation. BP, HR, RR, BMP. Utilize in conjunction with adequate sedation and/or analgesia. Mechanical Ventilation is required.     | Paralysis, neuromuscular blocker, must have full ventilator support at all times<br>Ideal Body Weight (IBW) may be used on obese patients for dose calculation   |
| Cosyntropin                  | ALL  | Diagnostic               | Over 2 min   | 250 mcg  | Reconstitute with diluent provided.<br><br>Reconstitute 250mcg mg with NS 2-5 mL if diluent not available. | Monitor HR, BP. Observe patients twice (15 min apart) for the first 30 min after injection for possible allergic reaction. Observe frequently thereafter. Monitor BP. | Monitor for anaphylaxis  |
| Dantrolene<br>(Dantrium)     | OR, ICU, FBP PACU, RAD ONC?  | Skeletal Muscle Relaxant | 1 min  | 2.5mg/kg   | Reconstitute vial with 60 mL sterile water for injection without a bacteriostatic agent                    | Motor function (rigidity), RR, HR, BP for 24 hours; Creatinine Kinase; Max total dose = 10 mg/kg/day  | Dantrolene, Flushing, Dyspnea  |
| Dexamethasone<br>(Decadron)  | ALL  | Corticosteroid           | Over 3 - 5 Min   | 20mg   | Do not dilute  | BMP, Glucose, BP. May mask signs of infection.  |  |
| Dextrose (D50%)              | ALL  | Simple sugar             | steady push over   | 25 g   | Do not dilute  |   | Rapid fluid and electrolyte shift, see   |

| GENERIC NAME<br>(BRAND NAME)  | UNIT<br>SPECIFICATION           | DRUG CLASS              | IVP RATE              | MAXIMUM SINGLE<br>DOSE | DILUTIONS  | MONITORING CONSIDERATIONS   | ADVERSE REACTIONS/COMMENTS   |
|-------------------------------|---------------------------------|-------------------------|-----------------------|------------------------|--|---|--|
|                               |                                 |                         | 1 min                 |                        |  |   | hypoglycemia protocol  |
| Diazepam<br>(Valium)          | ALL                             | Benzodiazepine          | 5 mg/min              | 10 mg                  | Do not dilute<br>ADMINISTER<br>THROUGH LOWEST Y-<br>SITE OF RAPIDLY<br>RUNNING FLUID   | RR, HR, BP, sedation. Effects reversed by flumazenil  | Use in large vein; monitor for extravasation, ↓RR, ↓BP   |
| Digoxin (Lanoxin)             | CCCDU, IMC, C-T, MS-T, MS       | Digitalis glycoside     | 0.25 mg/ 5 min        | 0.5 mg/ 5 min          | Can be administered undiluted or diluted with 10mL of NS. May be administered undiluted or diluted fourfold in D5W, NS, or SWFI for direct injection. Less than fourfold dilution may lead to drug precipitation. (Lexicomp) | Apical pulse, HR, BP, baseline, continuous cardiac monitoring, BMP (K, Mg, Ca), serum digoxin levels<br>***Loading dose is given in a setting with continuous cardiac monitoring, monitor HR for minimum 30 minutes after loading dose*** | Bradycardia, hypokalemia, electrolyte imbalances potentiate toxicity   |
| Diltiazem<br>(Cardizem)       | CC, CDU, IMC, C-T               | Calcium channel blocker | 2 min                 | 0.35 mg/kg             | Do not dilute  | HR, BP, baseline ECG<br>***Loading dose is given in a setting with continuous cardiac monitoring, monitor HR for minimum 30 minutes after loading dose***   | ↓ BP, ↓ HR   |
| Diphenhydramine<br>(Benadryl) | ALL                             | Antihistamine           | 25 mg/min             | 50 mg                  | Do not dilute  |   | ↓ U/O, delirium in elderly   |
| Droperidol<br>(Inapsine)      | CC                              | Neuroleptic, antiemetic | Over 2-5 min          | 0.625-2.5 mg           | Do not dilute  | EKG, vital signs, monitor for QTc prolongation (consider checking EKG prior to dose and continue for 2-3 hours after completing treatment), monitor for symptoms of EPS (e.g., dystonia)  | Black Box Warning=Cases of QT prolongation and torsade de pointes, including some fatal cases, have been reported. |
| Enalaprilat<br>(Enalapril)    | CC, IMC                         | Ace-inhibitor           | 0.625 mg-1.25 mg/5min | 1.25 mg                | Do not dilute  | Monitor K+, SCr<br>– Continuous cardiac monitoring; monitor BP every 15 minutes for 30 minutes after administration   | ↓ BP, marked hypotension, slower administration in patients at risk of hypotension (i.e, CHF, AMI, diuretics)      |
| Epinephrine<br>(Adrenaline)   | Any units during a code blue A. | Sympathomimetic         | Rapid IV push.        | 1 mg                   |  | BP, HR, RR  |  |
| Eptifibatide<br>(Integrilin)  | CC, IMC, C-T, CVPR,             | Antiplatelet Agent      | 1 to 2 mins           | 22.6 mg                | Do not dilute  | Monitor for Hgb/Hct, and platelets. Dose adjustments based on renal function. Maximum infusion rate based on weight and renal function. Actual body weight should be used to calculate creatinine clearance and the medication dose.      | Hypotension, Thrombocytopenia, Bleeding  |
| Etomidate                     | CC CODE BLUE                    | General                 | 30 to 60 secs         | 0.6mg/kg               | Do not dilute  | Monitor for BP, HR, Respiratory   | Injection site pain, Adrenal Suppression   |

| (Amidate)                       | A  | Anesthetic              |                              |                      |  | Rate, and sedation.<br>May be given undiluted; avoid administration into small vessels.  |   |
|---------------------------------|--|-------------------------|------------------------------|----------------------|--|--|---|
| GENERIC NAME<br>(BRAND NAME)    | UNIT SPECIFICATION                                 | DRUG CLASS              | IVP RATE                     | MAXIMUM SINGLE DOSE  | DILUTIONS  | MONITORING CONSIDERATIONS  | ADVERSE REACTIONS/COMMENTS  |
| Famotidine<br>(Pepcid)          | ALL  | H2 antagonist           | 2 min                        | 20 mg                | 5-10 mL NS   | None   | H/A, N/V  |
| Fentanyl<br>(Sublimaze)         | ALL  | Narcotic analgesic      | Over 2 min                   | 2mcg/kg              | Do not dilute (small doses) or may dilute with 5 mL NS 0.9% or sterile water for injection   | Assess at baseline and peak effect :<br>BP, HR, RR   | Use with caution in patients with BMI >40   |
| Flumazenil<br>(Romazicon)       | All units during code Blue A or rapid response, CC | Benzodiazepine antidote | Over 15-30 sec               | 1 mg                 | Do not dilute  | Monitor BP, HR, and RR closely. ECG and pulse oximetry are recommended. Observe continuously for re-sedation and respiratory depression for an appropriate period (2 or more hours).         | Duration of action is shorter than benzodiazepines, monitor for sedation, ↑ seizure risk  |
| Furosemide<br>(Lasix)           | ALL  | Diuretic                | 20 mg/min                    | 1 mg/kg up to 120 mg | Do not dilute  | BP, BMP, CO2, urine output   | Ototoxicity, ↓BP, ↓ electrolytes, ↓ fluid volume  |
| glucagon                        | ALL  | Antidote                | 5-10 mg/min                  | 10 mg                | Reconstitute with 1mL of sterile water.  | Monitor HR, BP, RR, blood glucose  | Hypotension, hypertension, nausea, vomiting<br><br>**Rapid injection may be associated with increased N/V; place patient in lateral recumbent position to protect airway and to prevent choking when consciousness returns. |
| Haloperidol<br>(Haldol)         | ALL  | Antipsychotic           | 5mg/min.                     | 10 mg                | 5-10 mL NS   | Resolution of agitation and delirium. Obtain baseline ECG prior to treatment. Monitor for EPS, sedation and BP. Doses >= 35 mg per day have increased risk of QTc prolongation. Monitor ECG. | ↓ BP, EPS (dystonia, rigidity, tremors), potential for QT prolongation<br>Non-ICU = 35 mg/day, PRN only   |
| Heparin                         | ALL  | Anticoagulant           | 5,000 units/min              | Per protocol         | Do not dilute  | Monitor PTT  | Prolonged bleeding time   |
| Hydralazine<br>(Apresoline)     | CCCDU IMC, C-T, MS-T, FBP                          | Anti-hypertensive       | 10 mg/min                    | 20 mg                | Do not dilute  | – Monitor BP every 10 minutes for 20 minutes after administration.<br>– May need more frequent BP monitoring based on clinical situation.  | Angina, MI, ↓ BP, additive with meds, ↓CPP, caution in CVA or with epinephrine  |
| Hydrocortisone<br>(Solu-cortef) | ALL  | Corticosteroid          | 100mg/30sec ;<br>200mg/min); | 200 mg               |  | BP, electrolytes, blood glucose, edema may mask signs of infection   |   |
| Hydromorphone<br>(Dilaudid)     | ALL  | Narcotic analgesic      | 0.5mg/min                    | 2 mg                 | Do not dilute  | Assess at baseline and peak effect :HR, BP, RR<br>Effects reversed by naloxone. Please see naloxone section for more information.  | Note: 7-8 times more potent than morphine. Use with caution in patients with BMI >40<br>↓RR, ↓ HR, ↓ BP   |
| Insulin Regular                 | ALL  | Hormone                 | Over 10 sec                  | (30units)            | Central line – Draw up dose in insulin syringe. Dilute in 10mL normal saline flush syringe.<br><br>Peripheral line – Draw up dose in insulin | Monitor electrolytes and glucose   |   |

| GENERIC NAME<br>(BRAND NAME) | UNIT<br>SPECIFICATION  | DRUG CLASS          | IVP RATE   | MAXIMUM SINGLE<br>DOSE   | DILUTIONS   | MONITORING CONSIDERATIONS  | ADVERSE REACTIONS/COMMENTS   |
|------------------------------|--|---------------------|--|--|---|--|--|
|                              |  |                     |  |  | syringe. Dilute in 3mL normal saline flush syringe.   |  |  |
| Ketamine (Ketalar)           | CODE BLUE A, The RN may only administer Ketamine IV push for RSI when the prescribing physician is present performing the procedure with both hands engaged. In this instance the RN is acting only in the capacity of a second pair of hands. | General Anesthetic  | Over 2 mins  | 2 mg/kg  | The 50 mg/mL and 100 mg/mL vials may be diluted in D5W or NS to prepare a maintenance infusion with a final concentration of 1 mg/mL (or 2 mg/mL in patients with fluid restrictions) | Monitor for sedation score, RR, BP, and HR every 15 mins for 1st hour, then q1h; may increase oral secretions.   | Hypertension, Tachycardia, Emergence from anesthesia.  |
| Ketorolac (Toradol)          | ALL  | NSAID               | Administer IV bolus over a minimum of 15 seconds (Lexicomp). | 30 mg  | Do not dilute   | BP   | GI bleed, ↑ BP, edema, renal toxicity Max daily dose for <65 years old = 120 mg; ≥ 65 years old, < 50 kg, or renally impaired = 60 mg. Renal function, BP, LFTs, urine output, CBC. Maximum duration 5 days due to risk of GI bleed. |
| Labetalol (Normodyne)        | CC, CDU, IMC, C-T, MS-T, FBP   | Anti-hypertensive   | 10 mg/min<br><br><b>FBP=</b> 10-20 mg/min                    | 40 mg<br>Additional doses of may be given at 10 minute intervals until desired BP is achieved or up to a total of 300 mg<br><br><b>FBP=</b> 80mg/dose<br>Max cumulative dose = 220mg/24hr per order set and ACOG | Do not dilute   | Continuous cardiac monitoring ( <u>except FBP</u> ): HR, BP every 15 minutes for 30 minutes after administration | ↓ BP, ↓ HR   |
| Levothyroxine (Synthroid)    | ALL  | Thyroid replacement | 50 mcg/min   | 200 mcg  | Reconstitute as directed; dilute with 5cc NS  | HR, BP, TFTs   | Tachyarrhythmias. Use immediately after reconstitution (fluid not stable-product is only stable for 4 hours. Discard unused portion.   |
| Lidocaine                    | CC, Code Blue A  | Antiarrhythmic      | Code Blue A-seconds; Non-Code- 25-50 mg/min                  | 1.5 mg/kg  | Do not dilute   | HR, BP, ECG, mental status,  |  |
| Lorazepam (Ativan)           | ALL  | Benzodiazepine      | 2 mg/min   | 4 mg   | Dilute with equal volume of NS Mix thoroughly by gently inverting the container until homogenous; do not shake vigorously (Micromedex).   | Sedation, RR, BP, HR   | ↓ RR, apnea  |

| Magnesium   | Code Blue A        | Electrolyte           | Over 1 to 2 minutes | 2 g  | Dilute with equal volume of NS or D5W   | HR, BP, ECG   | IVP-Emergency Use Only<br>If non-emergent replacement, use infusion   |
|---|--------------------|-----------------------|---------------------|--|---|---|---|
| GENERIC NAME (BRAND NAME)                         | UNIT SPECIFICATION | DRUG CLASS            | IVP RATE            | MAXIMUM SINGLE DOSE  | DILUTIONS   | MONITORING CONSIDERATIONS   | ADVERSE REACTIONS/COMMENTS  |
| Meperidine (Demerol)                              | CC, 2W, , FBP      | Narcotic analgesic    | Over 2-5 min        | 50 mg  | IV push should be administered using a diluted solution, use of a 10 mg/mL concentration has been recommended (Lexicomp)  | Assess at baseline and peak effect :HR, BP, RR<br>Effects reversed by naloxone.<br>Please see naloxone section for more information.  | Restricted to drug-induced rigors/consult with pharmacist. Caution in patients with renal dysfunction-seizure risk. Monitor for twitching, jerking, shaky hands, tremors  |
| Methyl-prednisolone Sodium Succinate (Solumedrol) | ALL                | Cortico-steroid       | 40 mg/min           | 125 mg   |   | BP, electrolyte changes, serum/blood glucose, edema; may mask signs of infection  |   |
| Metoclopramide (Reglan)                           | ALL                | Anti-emetic           | 2 min               | 10 mg  | Do not dilute   | Sign and symptoms of tardive dyskinesia (or other extrapyramidal symptoms), mental status, improvement in nausea/vomiting   | Anxiety, restlessness, drowsiness, EPS  |
| Metoprolol (Lopressor)                            | CC, FBP, IMC, CDU  | Beta-blocker          | 5 mg/min            | 5 mg   | Do not dilute   | Continuous cardiac monitoring: <b>Bedside monitor required.</b> HR, BP every 15 minutes for 30 minutes after administration.  |   |
| Midazolam (Versed)                                | CC                 | Benzodiazepine        | Over 2 min          | 2 mg   | Do not dilute   | HR, BP, RR, mental status. May be prolonged effects in elderly, renal or hepatic dysfunction.   | Moderate sedation policy, see RSI guidelines for intubation   |
| Morphine (Morphine)                               | ALL                | Narcotic analgesic    | 1 mg/min            | 10 mg  | Do not dilute   | Assess at baseline and peak effect :HR, BP, RR<br>Effects reversed by naloxone.<br>Please see naloxone section for more information   | ↓RR, ↑HR, ↓BP; Use with caution in patients with BMI >40  |
| Naloxone (Narcan)                                 | ALL                | Opioid antagonist     | 30 sec              | 2 mg<br><br>If using 0.4 mg diluted with 9 ml NS (0.04mg/ml):<br>• 0.1mg (2.5ml) increments at a time (see comments) | <ul style="list-style-type: none"> <li>• Dose 2mg: Do not dilute</li> <li>• Dose 0.4mg: dilute 0.4 mg (0.4mg/1 ml) in a syringe with 9 ml NS to a final concentration of 0.04mg/ml</li> </ul> | Monitor RR, HR, BP, and/or arrhythmia, reversal of opioid effects including s/s of opioid withdrawal (HTN, tachycardia, diaphoresis, flu-like symptoms, anxiety, restlessness). May repeat doses. Naloxone is NOT a harmless medication - cause serious life-threatening side effects such as: flash pulmonary edema, significant arrhythmias, hypertension, seizures, cardiac arrest, and reversal of opioid analgesic effects | <p>↑RR, ↑HR, ↑BP, high doses ↑VT/VF, Opioid may outlast Naloxone, see Narcan pathway and/or PCA pathway</p> <p>Start with low dose 0.1 mg (2.5 ml – see dilution) increments at a time for a total of 0.4 mg (10ml) over 2 min if opioid-related sedation and respiratory depression or post-op</p> |
| Ondansetron (Zofran)                              | ALL                | Anti-emetic           | Over 2 min          | 4 mg   | Do not dilute   | HR, BP after to monitor for orthostatic hypotension - ambulate slowly; ECG if electrolyte abnormality or QT prolongation  |   |
| Pantoprazole (Protonix)                           | ALL                | Proton Pump Inhibitor | 2 min               | 40 mg  | 10 mL NS  | Headache  |   |

| GENERIC NAME<br>(BRAND NAME)    | UNIT<br>SPECIFICATION  | DRUG CLASS              | IVP RATE   | MAXIMUM SINGLE<br>DOSE   | DILUTIONS  | MONITORING CONSIDERATIONS  | ADVERSE REACTIONS/COMMENTS  |
|---------------------------------|--|-------------------------|--|--|--|--|---|
| Phenobarbital<br>(Luminal)      | CC   | Barbiturate             | 60 mg/min  | 200 mg   | Do not dilute                                      | BP, RR   | IV route usually reserved for critical situations and preferred in patients with a protected airway since it can cause significant respiratory depression with repeated dosing. Use caution in elderly and those with impaired renal or hepatic function. |
| Prochlorperazine<br>(Compazine) | ALL  | Anti-emetic             | 5 mg/min   | 10 mg  | Do not dilute                                      | BP   | ↓BP, EPS (dystonia, rigidity, tremors)  |
| Propofol<br>(Diprivan)          | <b>Nurses in Maryland Per Board of Nursing Cannot Administer I.V. Push</b> |                         |  |  |  |  |   |
| Rocuronium                      | CC   | Paralytic               | Over 1-2 min   | 1.2 mg/kg  | Do not dilute                                      | Train of 4 via peripheral nerve stimulation. BP, HR, RR, BMP. Utilize in conjunction with adequate sedation and/or analgesia.. Mechanical Ventilation is required. | Paralysis; neuromuscular blocker, must have full ventilator support at all times  |
| Sodium Bicarbonate              | CC Code Blue A<br><b>Any units for hyperkalemia with EKG changes</b>       | Alkalinizing agent      | Over 5-30 seconds  | 1 mEq/kg   | Do not dilute                                      | Electrolytes. ABG. Signs and symptoms of fluid retention, RR   | Do not mix with Calcium products or Catecholamines, flush line before and after administration with NS  |
| Succinylcholine                 | CC   | Paralytic               | Seconds<br><br>May be administered undiluted by rapid IV injection (Lexicomp). | 2 mg/kg<br><br>Intubation: 0.6 mg/kg (range: 0.3 to 1.1 mg/kg).<br>Intubation (rapid sequence) (off-label dosing): 1 to 1.5 mg/kg<br>Long surgical procedures (intermittent IV): Initial 0.3 to 1.1 mg/kg. (Lexicomp). | Do not dilute                                      | Train of 4 via peripheral nerve stimulation. BP, HR, RR, BMP. Utilize in conjunction with adequate sedation and/or analgesia.. Mechanical Ventilation is required. | Paralysis; neuromuscular blocker, must have full ventilator support at all times. Hyperkalemia is contraindicated   |
| Thiamine<br>(Vitamin B1)        | ED Only, All other floors administer in I.V. Mini-Bag                      | Vitamin                 | Over 5 min   | 100 mg   | Do not dilute                                      | HR, BP, RR, contains aluminum- may develop a hypersensitivity or life-threatening anaphylactic reaction to thiamine, especially after repeated injections          | Given prior to glucose as I.V. push to avoid Wernicke's Encephalopathy  |
| Vasopressin                     | CC, Code Blue A  | Hormone                 | Rapidly  | 40 units   | Do not dilute                                      | Monitor ECG, HR, BP  |   |
| Vecuronium<br>(Norcuron)        | CC   | Neuromuscular blocker   | Over 1-2 min   | 0.1 mg/kg, Max 10 mg   | Dilute vial with 10 mL of NS/sterile water 1 mg/mL | Train of 4 via peripheral nerve stimulation. BP, HR, RR, BMP. Utilize in conjunction with adequate sedation and/or analgesia.. Mechanical Ventilation is required. | Neuromuscular blocker, must have full ventilator support at all times   |
| Verapamil (Calan)               | Code Blue A, CC, IMC, C-T  | Calcium channel blocker | 2.5 mg/min<br>Not less than 2 min and for geriatric patients                   | 10 mg  | Do not dilute                                      | HR, BP, ECG  | ↓ BP, ↓ HR  |

|  |  |  |                        |  |  |  |  |
|--|--|--|------------------------|--|--|--|--|
|  |  |  | not less than 3<br>min |  |  |  |  |
|--|--|--|------------------------|--|--|--|--|

8/31/18